Rocket Pharmaceuticals is trading 10% down at $3.02 amid broad weakness across biotechnology and risk assets. - The XBI biotech ETF is down 2.04%; major U.S. indexes are also lower as rising oil prices and Treasury yields pressure growth-oriented stocks. - No fresh company-specific announcement or adverse catalyst has been identified for September 23, 2026. Recent FDA alignment and favorable analyst coverage were previously reported, not new negative developments.